https://www.selleckchem.com/products/sbi-477.html
Nine of the 11 responders had tumors with B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF; n=6) and/or NRAS Proto-Oncogene, GTPase (NRAS; n=3) mutations. Forty-six patients had stable disease (SD). #link# In patients with ocular melanoma (n=13), best overall response was PR (n=1), SD (n=11), and disease progression (n=1). Phosphorylated extracellular signal-regulated kinase (pERK) levels were substantially reduced within 2h of treatment and inhibition was sustained with continuous twice-daily dosing. Treatment-related, recurrent, gr
Like
Comment
Share
